Retatrutide's Next Trial Isn't Clinical

If you're new to Drugstore Cowboy, welcome.

This past weekend, I had the unexpected privilege of being quoted in a New York Times opinion piece where this newsletter was referred to as "frequently funny and always informative."

I promise to do my best to live up to that description.

If this is your first time reading, here's what you should know about me to get up to speed.

I'm a practicing pharmacist and owner of C.O. Bigelow, the oldest pharmacy in America. I love clinical trials and hard evidence. I believe FDA approval still matters. And I'm endlessly fascinated by the intersection of medicine, business, and regulation because, more often than not, that's where the biggest stories in healthcare are actually happening.

Today's story is a perfect example.

Earlier this year, I wrote an entire piece explaining why I believe retatrutide could become the most important drug of the next decade. If you missed it, I'd encourage you to read that first. Today's article isn't really about retatrutide itself. It's about the legal battle quietly unfolding around it, and why I think it may end up shaping the future of obesity medicine just as much as the drug's clinical performance.

Last month, Eli Lilly announced another set of outstanding retatrutide Phase 3 trial results. Adults with obesity and type 2 diabetes lost up to 20.8% of their body weight after 80 weeks. Adults with severe obesity and cardiovascular disease lost up to 22.6%, reinforcing the extraordinary results we've already seen from earlier studies. The company also announced that it now has the clinical package needed to seek FDA approval.

Those numbers further exhibit why I believe retatrutide is about to take the world by storm.

But they weren't the most interesting part of the announcement.

Buried in the release was a sentence that almost everyone skipped over.

Lilly said it plans to submit retatrutide through a Biologics License Application (BLA) in early 2027.

To most people, that probably sounds like meaningless regulatory jargon.

I think it could end up being worth tens of billions of dollars and shape the future of medication access in the United States.

To understand why, you first have to understand something important about our drug classification system.

Not every prescription medicine is legally treated the same.

Some medicines are regulated as traditional drugs, often referred to as small molecules.

Others are regulated as biologics.

To the average patient, the distinction is invisible.

To Eli Lilly, it could determine the future of one of the most valuable medicines ever developed.

The difference isn't simply semantic.

Traditional drugs (small molecules) eventually face generic competition through a well-established pathway. (For more on this, read my piece about the drug development pipeline.) Drug companies usually get around five years of exclusivity before competitors can bring generic alternatives to market.

Biologics follow an entirely different system built around biosimilars, which are a fancy word for generics but dramatically more difficult and expensive to develop. Competition generally arrives years later, fewer companies participate, and the original manufacturer often retains meaningful pricing power for much longer.

That's why this matters.

Retatrutide isn't just fighting for FDA approval.

It's fighting to determine how many years of price control and market leadership it will have.

Here's where the story gets genuinely fascinating.

Retatrutide isn't obviously one thing or the other.

It's a peptide.

Federal law has historically treated peptides differently depending on their characteristics, and one of the factors regulators have considered is size. Generally, if a peptide is made up more than 40 amino acids, then it's a biologic. Retatrutide sits almost exactly on the boundary that has become central to this debate, containing roughly 40 amino acids.

That's important because it means Eli Lilly isn't trying to skirt the rules and convince the FDA that aspirin is secretly a biologic.

There is a legitimate scientific and legal argument here.

Reasonable people can disagree about where the line belongs.

The problem is that once you appreciate the financial implications, it becomes impossible to pretend this is merely an academic debate.

If the FDA ultimately agrees that retatrutide belongs in the biologics category, the decision won't just affect one drug.

It will influence how future obesity medicines are developed, protected, and commercialized.

Drug companies are paying attention.

So are investors.

So are compounding pharmacies.

If you've been reading Drugstore Cowboy for a while, you already know where I stand on compounding.

If you're new, here's the short version.

I believe compounding of commercially available brand-name medications like GLP-1s is dangerous and completely driven by greed masquerading as patient access. More importantly, I believe it puts our entire drug patent system at risk of collapsing because it undermines the economic model that has produced nearly every major pharmaceutical breakthrough of the last half century. Unfortunately, drug companies need to be allowed to profit off their research in order to develop more amazing drugs.

That doesn't mean I totally ignore the tradeoffs.

The argument made by compounders and many patient-access advocates is straightforward.

If retatrutide becomes a biologic, competition becomes harder. Biosimilars are more difficult to develop than traditional generics, and crucially are not allowed to be compounded by 503A or 503B facilities like Ozempic and the other GLP-1s currently on the market. Patients may wait longer for lower prices. Telehealth companies built around compounded GLP-1s would almost certainly see fewer opportunities. Healthcare spending could remain elevated for years.

Those are real concerns.

I don't dismiss them.

But I think there's another side to the equation that deserves equal attention.

The obesity market has spent the last several years blurring distinctions between FDA-approved medicines, compounded versions, research peptides, and products sold somewhere in between. The result has been a marketplace where patients often struggle to understand what they're actually buying.

Personally, I don't think that's healthy for medicine.

That's also why I don't view Lilly's position as some cynical legal trick.

Companies absolutely push regulatory boundaries when billions of dollars are at stake.

But there's an important difference between exploiting a loophole and making a legitimate argument inside a gray area of the law.

I think this case falls into the second category.

In many ways, this feels like a direct consequence of the FDA's handling of GLP-1 compounding over the past several years. If regulators had drawn firmer boundaries around the first generation of GLP-1s, I'm not convinced Lilly would feel the need to push so aggressively for biologic status now.

Companies respond to incentives. Lilly is responding to the incentives the FDA created.

Retatrutide occupies one of the grayest areas in pharmaceutical regulation. Lilly has been arguing for years that it belongs under the biologics framework, eventually challenging the FDA's position in court. The company hasn't yet received that determination, but its decision to publicly announce plans to file a Biologics License Application suggests it believes the path forward has become substantially clearer, even though the FDA will ultimately make that decision after reviewing the application.

Whether Lilly is right is ultimately for regulators and the courts to decide.

But I don't think the argument itself is frivolous.

There is one more piece of this story I'll be watching closely.

Under most administrations, I'd expect this dispute to remain largely between FDA scientists, agency lawyers, and Eli Lilly.

I'm less certain today.

The Trump administration has shown a willingness to involve itself in FDA policy in ways previous administrations generally avoided (see last week's peptide hearings). At the same time, Lilly CEO Dave Ricks appears to have developed one of the closest working relationships between a pharmaceutical executive and the White House.

I have no evidence that those facts will influence the outcome of this case.

But I'd be surprised if they weren't part of the broader context.

The stakes are simply too large.

Most Americans will never hear the phrase "Biologics License Application."

They'll never read the court filings.

They'll never think about amino acid counts or statutory definitions.

What they'll notice is whether retatrutide costs $400 a month or $1400. Whether Medicare spends billions more. Whether telehealth companies can legally offer compounded versions. Whether competitors arrive in five years or fifteen.

Those consequences are very real.

And they may ultimately hinge on a legal definition that almost nobody outside the pharmaceutical industry even knew existed.

Retatrutide has already won in the laboratory.

Now comes the fight over what kind of drug it is.

I may end up being wrong. The FDA could reject Lilly's argument outright.

But if I'm right, we're watching one of the most consequential regulatory fights in modern pharmaceutical history unfold in real time.

Giddy up!!!

Alec Wade Ginsberg, PharmD, RPh
4th-Gen Pharmacist | Owner & COO, C.O. Bigelow
Founder, Drugstore Cowboy